伊立替康联合米托恩醌治疗难治/复发性非霍奇金淋巴瘤的疗效观察  

Effects of irinotecan combined with mitoxantrone regimen in treatment of refractory or relapsing non-Hodgkin lymphoma

作　　者：吴晓雄[1] 曹永彬[1] 刘周阳[1] 王志红[1] 徐丽昕[1] 刘蓓[1] 闫蓓[1] 马健[1] 

机构地区：[1]解放军总医院第一附属医院血液科,北京100037

出　　处：《临床血液学杂志》2009年第4期366-367,共2页Journal of Clinical Hematology

摘　　要：目的:在国内首次报道伊立替康(开普拓)联合米托恩醌治疗难治和复发非霍奇金淋巴瘤(NHL)的疗效;为难治性NHL的治疗寻找新的方法。方法:采用开普拓联合米托恩醌为主的化疗方案治疗21例难治和复发NHL,评价其疗效及不良反应。结果:7例(33.3%)难治和复发NHL达完全缓解(CR);8例(38.1%)达部分缓解(PR);总有效率为71.4%。不良反应主要为骨髓抑制、迟发性腹泻以及胃肠道反应,患者均能耐受。结论:开普拓联合米蒽醌对NHL特别是部分难治和复发NHL仍有效,不良反应可以耐受。可用于治疗对其他化疗方案无效的难治和复发NHL。Objective：To evaluate the effects of irinotecan combined with mitoxantrone regimen in treatment of refractory and relapsing lymphoma. Method： Twenty-one patients with refractory or relapsing non-Hodgkin lymphomas were treated with IMOP regimen （including irinotecan, mitoxantrone, vineristine, prednisone）. Result： The results showed that the rate of complete remission was 33.3% （7/21）, the rate of partial remission was 38. 1% （8/21）, and the overall response rate was 71.4%. Mainly side effects included digestive toxicities （nausea/ vomiting, diarrhea, ere） and myelosuppression （neutropenia, anemia, thromboeytopenia, etc）, but no patient deaded. Conclusion：It is concluded that irinotecan combined with mitoxantrone regimen was effective in patients with refractory or relapsing non-Hodgkin lymphomas who were no respond to other regimen, and the regimen was safe.

关 键 词：非霍奇金淋巴瘤 难治 复发 伊立替康 疗效 

分 类 号：R733.4[医药卫生—肿瘤]